School of Science grows by 10 – MIT News

Despite the upheaval caused by the coronavirus pandemic, 10 new faculty members have joined MIT in the departments of Biology; Chemistry; Earth, Atmospheric and Planetary Sciences; Mathematics; and Physics. The School of Science welcomes these new faculty, most of whom began their appointment July 1, amidst efforts to update education and research plans for the fall semester. They bring exciting and valuable new areas of strength and expertise to the Institute.

Camilla Cattania is an earthquake scientist. She uses continuum mechanics, numerical simulations, and statistics to study fault mechanics and earthquake physics at different scales, from small repeating events to fault interaction on regional and global scales. The models she has developed can help forecast earthquake sequences caused by seismic or aseismic events, such as aftershocks and swarms induced by forcing mechanisms like magma moving under the Earths surface. She has also developed theoretical models to explain why certain faults rupture in predictable patterns while others do not. Cattanias research plans include widening her focus to other tectonic settings and geometrically complex fault structures.

Cattania earned her bachelors and masters degrees from Cambridge University in experimental and theoretical physics in 2011, after which she completed a PhD in Germany at the GFZ German Research Center for Geosciences and the University of Potsdam in 2015. Subsequently, she spent a few months as a researcher at Woods Hole Oceanographic Institution and as a postdoc at Stanford University and her doctoral institution. She joins the Department of Earth, Atmospheric and Planetary Sciences as an assistant professor.

Richard Fletcher researches quantum physics using atomic vapors one-millionth the density of air and one-millionth the temperature of deep space. By manipulating the gas with intricately sculpted laser beams and magnetic fields, he can engineer custom-made quantum worlds, which provide both a powerful test bed for theory and a wonderful playground for discovering new phenomena. The goal is to understand how interesting collective behaviors emerge from the underlying microscopic complexity of many interacting particles. Fletchers interests include superfluidity in two-dimensional gases, methods to probe the correlations between individual atoms, and how the interplay of interactions and magnetic fields leads to novel physics.

Fletcher is a graduate of Cambridge University, where he completed his bachelor's in 2010. Before returning to Cambridge University to earn his PhD in 2015, he was a research fellow at Harvard University. He originally came to MIT as a postdoc in 2016 and now joins the Department of Physics as an assistant professor. Fletcher is a member of the MIT-Harvard Center for Ultracold Atoms.

William Frank investigates deformation of the Earths crust. He combines seismology and geodesy to explore the physical mechanisms that control the broad continuum of rupture modes and fault instabilities within the Earth. His research has illuminated the cascading rupture dynamics of slow fault slip and how the aftershocks that follow a large earthquake can reveal the underlying behavior of the host fault. Frank considers shallow shifts that cause earthquakes down to deep creep that is all-but-invisible at the surface. His insights work to improve estimates of seismic hazards induced by tectonic dynamics, volcanic processes, and human activity, which can then inform risk prediction and mitigation.

Frank holds a bachelors degree from the University of Michigan in earth systems science, which he received in 2009. The Institut de Physique du Globe de Paris awarded him a masters degree in geophysics in 2011 and a PhD in 2014. He first joined MIT as a postdoc in 2015 before moving to the University of Southern California as an assistant professor in 2018. He now returns as an assistant professor in the Department of Earth, Atmospheric and Planetary Sciences.

Ronald Fernando Garcia Ruizadvances research on fundamental physics and nuclear structure largely through the development of novel laser spectroscopy techniques. He investigates the properties of subatomic particles using atoms and molecules made up of short-lived radioactive nuclei. Garcia Ruizs experimental work provides unique information about the fundamental forces of nature and offers new opportunities in the search beyond the Standard Model of particle physics. His previous research at CERN focused on the study of the emergence of nuclear phenomena and the properties of nuclear matter at the limits of existence.

Garcia Ruizs bachelors degree in physics was achieved in 2009 at Universidad Nacional de Colombia. After earning a masters in physics in 2011 at Universidad Nacional Autnoma de Mxico, he completed a doctoral degree in radiation and nuclear physics at KU Leuven in 2015. Prior to joining MIT, he was first a research associate at the University of Manchester from 2016-17 and then a research fellow at CERN. Garcia Ruiz has now joined the Department of Physics as an assistant professor. He began his appointment Jan. 1. He is also affiliated with the Laboratory for Nuclear Science.

Ruth Lehmann studies germ cells. The only cells in the body capable of producing an entire organism on their own, germ cells pass genomic information from one generation to the next via egg cells. By analyzing the organization of their informational material as well as the mechanics they regulate, such as the production of eggs and sperm, Lehmann hopes to expose germ cells unique ability to enable procreation. Her work in cellular and developmental biology is renowned for identifying how germ cells migrate and lead to the continuation of life. An advocate for fundamental research in science, Lehmann studies fruit flies as a model to unveil vital aspects of early embryonic development that have important implications for stem cell research, lipid biology, and DNA repair.

Lehmann earned her bachelors degree in biology from the University of Tubingen in Germany. She took an interlude from her education to carry out research at the University of Washington in the United States before returning to Germany. There, she earned a masters equivalent from the University of Freiburg and a PhD from the University of Tubingen. Lehmann was subsequently a postdoc at the Medical Research Council Laboratory of Molecular Biology in the UK, after which she joined MIT. A faculty member and Whitehead Institute for Biomedical Research member from 1988 to 1996, she now returns after 23 years at New York University. Lehmann joins as a full professor in the Department of Biology and is the new director of the Whitehead Institute forBiomedical Research.

As an astrochemist, Brett McGuire is interested in the chemical origins of life and its evolution. He combines physical chemistry experiments and analyses with molecular spectroscopy in a lab, the results of which he then compares against astrophysics observation. His work ties together questions about the formation of planets and a planets ability to host and create life. McGuire does this by investigating the generation, presence, and fate of new molecules in space, which is vast and mostly empty, providing unique physical challenges on top of chemical specifications that can impact molecular formation. He has discovered several complex molecules already, including benzonitrile, a marker of carbon-based reactions occurring in an interstellar medium.

McGuires BS degree was awarded by the University of Illinois at Urbana-Champaign in 2009. He completed a masters in physical chemistry in 2011 at Emory University and a PhD in 2015 at Caltech. He then pursued a postdoc at the National Radio Astronomy Observatory and the Harvard-Smithsonian Center for Astrophysics. He joins the Department of Chemistry as an assistant professor.

Dor Minzer works in the fields of mathematics and theoretical computer science. His interests revolve around computational complexity theory, or more explicitly probabilistically checkable proofs, Boolean function analysis, and combinatorics. With collaborators, he has proved the 2-to-2 Games Conjecture, a central problem in complexity theory closely related to the Unique-Games Conjecture. This work significantly advances our understanding of approximation problems and, in particular, our ability to draw the border between computationally feasible and infeasible approximation problems.

Minzer is not new to online education. After earning his bachelors degree in mathematics in 2014 and a PhD in 2018, both from Tel-Aviv University, he became a postdoc at the Institute for Advanced Study in Princeton, New Jersey. He joins the Department of Mathematics as an assistant professor.

Lisa Piccirillo is a mathematician specializing in the study of three- and four-dimensional spaces. Her work in four-manifold topology has surprising applications to the study of mathematical knots. Perhaps most notably, Piccirillo proved that the Conway knot is not "slice." For all other small knots, "sliceness" is readily determined, but this particular knot had remained a mystery since John Conway presented it in the mid-1900s. After hearing about the problem at a conference, Piccirillo took only a week to formulate a proof. She is broadly interested in low-dimensional topology and knot theory, and employs constructive techniques in four-manifolds.

Piccirillo earned her BS in mathematics in 2013 from Boston College. Her PhD in mathematics was earned from the University of Texas at Austin in 2019, and from 2019-20 she was a postdoc at Brandeis University. She joins the Department of Mathematics as an assistant professor.

Jonathan Weissmans research interest is protein folding and structure, an integral function of life. His purview encompasses the expression of human genes and the lineage of cells, as well as protein misfolding, which can cause diseases and other physiological issues. He has made discoveries surrounding protein folding mechanisms, the development of CRISPR gene-editing tools, and other new therapeutics and drugs, and in the process generated innovative experimental and analytical methods and technologies. One of his novel methods is the ribosome profiling approach, which allows researchers to observe in vivo molecular translation, the process by which a protein is created according to code provided by RNA, a major advancement for health care.

Weissman earned a bachelors degree in physics from Harvard University in 1998 and a PhD from MIT in 1993. After completing his doctoral degree, he left MIT to become a postdoc at Yale University for three years, and then a faculty member at the University of California at San Francisco in 1996. He returns to MIT to join the Department of Biology as a full professor and a member of the Whitehead Institute for Biomedical Research. He is also a Howard Hughes Medical Institute investigator.

Yukiko Yamashita, a stem cell biologist, delves into the origins of multicellular organisms, asking questions about how genetic information is passed from one generation to the next, essentially in perpetuity, via germ cells (eggs and sperm), and how a single cell (fertilized egg) becomes an organism containing many different types of cells. The results of her work on stem cell division and gene transmission has implications for medicine and long-term human health. Using fruit flies as a model in the lab, she has revealed new areas of knowledge. For example, Yamashita has identified the mechanisms that enable a stem cell to produce two daughter cells with distinct fates, one a stem cell and one a differentiating cell, as well as the functions of satellite DNA, which she found to be crucial, unlike the waste they were previously thought to be.

Yamashita received her bachelors degree in biology in 1994 and her PhD in biophysics in 1999, both from Kyoto University. After being a postdoc at Stanford University for five years, she was appointed a faculty member at the University of Michigan in 2007. She joined the Department of Biology as a full professor with a July 1 start. She also became a member of the Whitehead Institute of Biomedical Research and is a standing investigator at the Howard Hughes Medical Institute.

The rest is here:
School of Science grows by 10 - MIT News

Faculty of Medicine researchers receive $2.8m for equipment and infrastructure – UBC Faculty of Medicine – UBC Faculty of Medicine

By Stephanie Chow | September 8, 2020

Eleven Faculty of Medicine researchers have received a combined $2.8 million for state-of-the-art labs and equipment.

The funding comes from the Government of Canada, through the Canada Foundation for Innovations (CFI) John R. Evans Leaders Fund. The investment provides researchers with the highly specialized infrastructure they need to be leaders in their field.

Deciphering DNA-encoded Gene-regulatory Logic with Genome-scale Synthetic DNA Carl de Boer, School of Biomedical Engineering

Infrastructure for Developing Pharmacologic Approaches to Modulating Fibrinolysis and Controlling Bleeding Disorders Christian Kastrup, Michael Smith Laboratories

Stem Cell and Genome Editing Lab Timothy Kieffer, Department of Cellular & Physiological Sciences

Community Hub for Arts-based Research and Innovation in Knowledge Translation Andrea Krusi, School of Population and Public Health

Exploring Mitochondria Function as Therapeutic Target in Acute Myeloid Leukemia and Multiple Myeloma Florian Kuchenbauer, Department of Medical Genetics

Hapscreen-RD: A Platform for Large-scale Screening of Human Haploid Cells for Rare Disease Research Josef Penninger, Life Sciences Institute & Department of Medical Genetics

Innovation in Mobility and Balance Rehabilitation Courtney Pollock, Department of Physical Therapy

The Stroke Management and eHealth Innovation Laboratory Brodie Sakakibara, Department of Occupational Science and Occupational Therapy, Southern Medical Program

Cryo-EM of Metabolic Enzymes for Drug Discovery Sriram Subramaniam, Department of Biochemistry

Investigating How Mitochondrial Stress Signaling Maintains Organelle Homeostasis in Health and Disease Hilla Weidberg, Department of Cellular & Physiological Sciences

Investigating the Neurophysiological Effects and Accumulation of Subconcussive Sports Head Impacts Lyndia Chun Wu, School of Biomedical Engineering

See the rest here:
Faculty of Medicine researchers receive $2.8m for equipment and infrastructure - UBC Faculty of Medicine - UBC Faculty of Medicine

BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia…

September 08, 2020 07:00 ET | Source: BeyondSpring, Inc.

- FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Prevention of Chemotherapy-Induced Neutropenia (CIN) -

- Designation Based on PROTECTIVE-2 Phase 3 Interim Data, Reinforcing Significant Treatment Need in CIN -

- Among the First Three Innovative Drugs to Receive Breakthrough Therapy Designations in China -

NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that its lead asset, first-in-class agent Plinabulin, has received the Breakthrough Therapy Designation (BTD) for the chemotherapy-induced neutropenia (CIN) indication from both the U.S. Food and Drug Administration (FDA) and Chinas Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

The FDA's BTD is intended to expedite the development and review of a drug candidate that is planned to treat a serious or life-threatening disease or condition in which clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.The CDE in China established its BTD program in July 2020 to facilitate the research and development of innovative drugs that treat severe life-threatening or quality-of-life impairing diseases with no existing therapy or with proven evidence to demonstrate clear clinical benefits compared to existing therapies. Products with BTD from the CDE may be considered for conditional approval and priority review when submitting New Drug Applications (NDAs).

"Receipt of Breakthrough Therapy Designation from the FDA acknowledges both the significant unmet need among patients with CIN and the highly encouraging clinical results generated by Plinabulin, said Douglas Blayney, M.D., global Principal Investigator for Plinabulins CIN studies and Professor of Medicine at the Stanford University School of Medicine. This should expedite Plinabulins move into the clinic, which is beneficial for patients. The currently approved CIN prevention agents are all G-CSF-based and not available to all patients. Even with the use of G-CSFs, over 80 percent of cancer patients undergoing chemotherapy may still experience Grade 4 neutropenia, which could lead to severe infection, hospitalization and even death. Thus, CIN still represents an unmet medical need.

"The clinical profile Plinabulin has shown truly represents a breakthrough in the CIN space since G-CSFs," added Ramon Mohanlal, M.D., Ph.D., MBA, Chief Medical Officer and Executive Vice President, Research and Development, at BeyondSpring. We look forward to continuing to work with the FDA as we advance the development of Plinabulin to address this urgent medical need.

The Breakthrough Therapy application is based on the strength of the totality of the clinical data generated so far:

The Company expects to report the full PROTECTIVE-2 Phase 3 topline data in Q4 2020 and file an NDA with the FDA by the end of 2020. The Company has submitted an NDA for Plinabulin for the CIN indication to the NMPA on a rolling basis in Q1 2020.

About Chemotherapy-Induced Neutropenia (CIN) CIN is a common side effect in cancer patients undergoing treatment that involves the destruction of a type of white blood cell, the neutrophil, which is a patients first line of defense against infections. Patients with Grade 4 (severe) neutropenia have an abnormally low concentration of neutrophils, which may lead to infections, hospitalization and death.

G-CSFs are the current standard of care for CIN prevention. However, G-CSFs have limitations in reducing Grade 4 neutropenia with high-risk chemotherapy. Neutropenia, if severe enough, may cause doctors to lower target doses of chemotherapy, end therapy early and / or delay chemotherapy cycles, each of which has a negative effect on long-term outcomes of cancer care.

Despite these limitations annual global use of G-CSFs is more than 4.3 million cycles per year (CPY). The U.S. (1.3 million CPY) and China (1.6 million CPY) account for more than two-thirds of the global CIN market. Plinabulins demonstrated clinical profile in combination with G-CSFs has the potential to build on this existing base and improve the standard of care for patients and practitioners.

About Plinabulin Plinabulin, BeyondSprings lead asset, is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). The durable anticancer benefits of Plinabulin have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation (Chem and Cell Reports, 2019). Plinabulins CIN data highlights the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice. Effects on HSPCs could explain the ability of Plinabulin to not only treat CIN but also to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34+ cells in patients.

About Plinabulin in CIN Study The PROTECTIVE-1 (Study 105) and PROTECTIVE-2 (Study 106) trials are both multicenter, double-blind, active controlled Phase 3 trials to support Plinabulins broad application in preventing CIN: Plinabulin for concurrent administration with myelosuppressive chemotherapy regimens in patients with non-myeloid malignancies for the presentation of chemotherapy-induced neutropenia (CIN).

PROTECTIVE-1 (Study 105)This study was designed to evaluate the safety and efficacy in non-small cell lung cancer (NSCLC), breast cancer and prostate cancer patients with risk factors, treated with docetaxel (Day 1 dose) in a 21-day cycle with a single dose of Plinabulin (40mg, Day 1 dose) versus a single dose of Neulasta (6mg, Day 2). Docetaxel is one example of an intermediate-risk chemotherapy. This is a non-inferiority study in CIN efficacy comparing Plinabulin and Neulasta in high-risk patients (intermediate chemotherapy, plus one or more additional risk factor). Study 105 Phase 3 interim data had achieved statistical significance based on the primary endpoint of the Duration of Severe Neutropenia (DSN) in the first cycle.

PROTECTIVE-2 (Study 106)This study was designed to evaluate the safety and efficacy in breast cancer, treated with docetaxel, doxorubicin and cyclophosphamide (TAC, Day 1 dose) in a 21-day cycle with Plinabulin (40 mg, Day 1 dose) in combination with Neulasta (6 mg, Day 2 dose) versus a single dose of Neulasta (6 mg, Day 2 dose) alone. TAC is an example of high-risk chemotherapy. Plinabulin and G-CSFs have complementary mechanisms in preventing chemotherapy-induced neutropenia (CIN). This is a superiority study in CIN efficacy in the rate of Grade 4 neutropenia prevention (primary endpoint), comparing the combination head-to-head against Neulasta, and is currently enrolling. Literature shows that the Grade 4 neutropenia rate for TAC and Neulasta at 6 mg is 83 to 93 percent, which presents severe unmet medical needs.

Covance is the clinical contract research organization (CRO) for patient recruitment and monitoring of global sites for this study. The CIN studies are conducted in over 60 clinical centers in the U.S., China and Europe. In addition, Absolute Neutrophil Count (ANC) data, which is used to calculate these endpoints, was obtained through central laboratory assessments by Covance Bioanalytical Methods using standardized and validated analytical tests.

About BeyondSpring Headquartered in New York, BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSprings first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medical needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen doses decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a pipeline drug, Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSprings extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed molecular glue that uses the protein degradation pathway.

Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSprings most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Media Contacts Caitlin Kasunich / Raquel Cona KCSA Strategic Communications ckasunich@kcsa.com / rcona@kcsa.com

Read more from the original source:
BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia...

Global Multiple Myeloma Treatment Market-Industry Analysis and forecast 2019 2027: By Application, Type, and Region. – Galus Australis

Global Multiple Myeloma Treatment Marketsize was valued US$ XX Mn. in 2019 and the total revenue is expected to grow at 11.34% from 2019 to 2027, reaching nearly US$ XX Mn.

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Multiple myeloma, also known as Kahlers disease, is a type of blood cancer of plasma cells that are found in the bone marrow. Multiple myeloma causes cancer cells to accrue in the bone marrow, where they attack the strong blood cells.

Multiple myeloma treatments have developed significantly above the last decade. New multiple myeloma treatments have provided efficient survival rates between myeloma patients. It has been also observed that the future drug pipeline of multiple myeloma is promising, biological drugs and stem cell-based therapies are likely to fuel the multiple myeloma treatment market in the upcoming years. On the other hand, the costs of radiotherapeutic equipment implementation, a limited number of target patients population, strict legal regulations are expected to hamper the market growth. Likewise, the MMR report contains a detailed study of factors that will drive and restrain the growth of the multiple myeloma treatment market globally.

Multiple Myeloma accounts for approximately 2.5% of the cancer-related deaths globally and is the second most major type of blood cancer next to Hodgkins Lymphoma. According to the World Cancer Research Fund, in 2018, above 159500 cases of multiple myeloma were diagnosed with the condition, where the occurrence rate among women and men was found in the ratio 1.2:1. The onset of the disease occurs after the age of 60. In recent times, the age of onset is drastically decreasing. In the year 2001, only two medications were available for treating multiple myeloma but now in 2020, 18 medicines are available. Moreover, there are over 25 FDA-approved drugs for treating multiple myeloma with therapeutics such as pomalidomide, carfilzomib, panobinostat, and ixazomib. The availability of new medications has given new hope for better treatments and better results and thus affecting the growth of the market as well. However, the survival of patients with a limited response while receiving treatment with primary immunodeficiency therapy remains poor and is one of the major challenges.

The MMR report covers the segments in the multiple myeloma treatment market such as type and application. By application, the hospital is expected to continue to hold the largest XX.85% share in multiple myeloma treatments market thanks to growing specialist doctors providing the best chance of long term survival.

North Americas multiple myeloma treatments market was valued at US$ XX.26 Mn. in 2019 and is expected to reach a value of US$ XX.13 Mn. by 2027, with a CAGR of 9.3%. The number of patients in the U.S is growing YoY with nearly 14600 new cases diagnosed annually. In 2017 alone there were approximately 142000 patients diagnosed for multiple myeloma.

Europe and the South African population are prone to develop multiple myeloma when compared with Asian economies. Though, the population in the APAC region outwits Europe and Africa. Further, growing the adoption rate of novel therapies, coupled with the support from the government along with non-government organizations and improving the survival of multiple myeloma patients.

The research study includes the profiles of leading players operating in the global multiple myeloma treatment market. Eli Lilly Company acquired ARMO Biosciences to develop immunotherapies for the treatment of cancer, hypercholesterolemia, inflammatory, and fibrosis diseases.

The objective of the report is to present a comprehensive analysis of the Global Multiple Myeloma Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Multiple Myeloma Treatment Market dynamics, structure by analyzing the market segments and projects the Global Multiple Myeloma Treatment Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Multiple Myeloma Treatment Market make the report investors guide. Scope of the Global Multiple Myeloma Treatment Market

Global Multiple Myeloma Treatment Market, by Applications

Hospitals Clinics Cancer Treatment and Rehabilitation Centers Global Multiple Myeloma Treatment Market, by Type

Proteasome Inhibitors Immunomodulatory Agents (IMiDs) Histone Deacetylase (HDAC) Inhibitors Immunotherapy Cytotoxic Chemotherapy Global Multiple Myeloma Treatment Market, by Region

Asia Pacific North America Europe South America Middle East & Africa Key players operating in Global Multiple Myeloma Treatment Market

Celgene Corporation Janssen Biotech, Inc. Bristol-Myers Squibb Company Novartis AG Cellectar Biosciences Inc. Millennium Pharmaceuticals Amgen, Inc. bbVie Genzyme Corporation Juno Therapeutics Eli Lilly and Company Glenmark Pharma

Global Multiple Myeloma Treatment Market Request For View Sample Report Page : @https://www.maximizemarketresearch.com/request-sample/65671 About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info: Name: Vikas Godage Organization: MAXIMIZE MARKET RESEARCH PVT. LTD. Email:[emailprotected] Contact: +919607065656 / +919607195908 Website:www.maximizemarketresearch.com

The rest is here:
Global Multiple Myeloma Treatment Market-Industry Analysis and forecast 2019 2027: By Application, Type, and Region. - Galus Australis

Worldwide Cell Therapy Industry to 2025 – North America is Leading the Cell Therapy Market – Yahoo Finance UK

Dublin, Sept. 07, 2020 (GLOBE NEWSWIRE) -- The "Cell Therapy Market- Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The cell therapy market will show rapid growth due to the increasing prevalence of chronic conditions, rising adoption of regenerative medicine and rise in the number of clinical studies pertaining to the development of cellular therapies.

Chronic diseases and conditions are on the rise worldwide. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. The emerging markets will be hardest hit, as population growth is anticipated be most significant in developing nations. Increased demand for healthcare systems due to chronic disease has thus become a major concern. Healthcare expenditures greatly increase, with each additional chronic condition with greater specialist physician access, emergency department presentations and hospital admissions.

Therefore the increasing prevalence of chronic conditions, government assistance and numerous companies investing heavily in stem cell therapy research and development will help to stimulate the industry growth. The proven effectiveness of cell therapy products coupled with increasingly favorable guidelines pertaining to cell therapy research and manufacturing should positively impact industry growth.

Key Market Trends

Allogeneic Therapies Segment Accounted for the Largest Share in the Cell Therapy Market

Allogeneic therapies rely on a single source of cells to treat many patients. They increase the risk of eliciting an immune response within a patient, and immunosuppressive therapies are sometimes administered in combination with allogeneic products. Therefore there is an increasing inclination of physicians towards therapeutic use of allogeneic therapies coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation.

Furthermore, the presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

North America is Leading the Cell Therapy Market

North America is estimated to retain the largest share of the market due to the presence of strong regulatory framework in order to promote cellular therapy development, the existence of industry bigshots, and high cost of therapies in the U.S. There is also the presence of leading universities that supports the research activities in the U.S. is one of the key factor driving the market for cell therapy in North America.

The Asia Pacific market is also increasing at a rapid rate due to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management.

Competitive Landscape

There has been a presence of a considerable number of companies that are collaborating with the blood centres and plasma collection centres in order to obtain cells for use in therapeutics development. These companies in partnership with blood banks and plasma banks are working together towards the advancement in the cell therapy market.

Reasons to Purchase this report:

Key Topics Covered:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increasing Prevalence of Chronic Conditions 4.2.2 Rising Adoption of Regenerative Medicine 4.2.3 Rise in Number of Clinical Studies Pertaining to the Development of Cellular Therapies 4.3 Market Restraints 4.3.1 High Cost of Therapies 4.4 Porter's Five Force Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Type 5.1.1 Autologous 5.1.2 Allogeneic 5.2 By Therapy 5.2.1 Mesenchymal Stem Cell Therapy 5.2.2 Fibroblast Cell Therapy 5.2.3 Hematopoietic Stem Cell Therapy 5.2.4 Other Therapies 5.3 By Application 5.3.1 Musculoskeletal 5.3.2 Malignancies 5.3.3 Cardiovascular 5.3.4 Dermatology & Wounds 5.3.5 Other Applications 5.4 Geography 5.4.1 North America 5.4.1.1 United States 5.4.1.2 Canada 5.4.1.3 Mexico 5.4.2 Europe 5.4.2.1 Germany 5.4.2.2 United Kingdom 5.4.2.3 France 5.4.2.4 Italy 5.4.2.5 Spain 5.4.2.6 Rest of Europe 5.4.3 Asia-Pacific 5.4.3.1 China 5.4.3.2 Japan 5.4.3.3 India 5.4.3.4 Australia 5.4.3.5 South Korea 5.4.3.6 Rest of Asia-Pacific 5.4.4 Middle-East and Africa 5.4.4.1 GCC 5.4.4.2 South Africa 5.4.4.3 Rest of Middle East and Africa 5.4.5 South America 5.4.5.1 Brazil 5.4.5.2 Argentina 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Anterogen Co., Ltd. 6.1.2 Tego Science 6.1.3 Chiesi Farmaceutici S.p.A. 6.1.4 Corestem Inc. 6.1.5 Pharmicell Co Ltd. 6.1.6 Fibrocell Technologies Inc 6.1.7 Nipro Corp 6.1.8 MEDIPOST 6.1.9 TiGenix (Takeda Pharmaceuticals) 6.1.10 Stempeutics Research Pvt. Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/bc5qc9

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

The rest is here:
Worldwide Cell Therapy Industry to 2025 - North America is Leading the Cell Therapy Market - Yahoo Finance UK

How Will the Virus Epidemic Cause Animal Stem Cell Therapy Market 2020 – Owned

Global Animal Stem Cell Therapy market research report provides the details about Industry Overview, Chain structure, Market Competition, Market Size and Share, SWOT Analysis, Technology, Cost, Raw Materials, Consumer Preference, Development and Trends, Regional Forecast, Company and Profile and Product and Service.

Animal Stem Cell Therapy market research report also gives information on the Trade Overview, Policy, Regional Market, Production Development, Sales, Regional Trade, Business Operation Data, Market Features, Investment Opportunity, Investment Calculation and other important aspect of the industry.

Request a Sample of Animal Stem Cell Therapy Market Research Report with 125 pages and Analysis of Top Key Players at https://www.insidemarketreports.com/sample-request/4/459572/Animal-Stem-Cell-Therapy

We make taking decisions easier, Accelerate Business through Strong Partnerships. We provide Research That Revolutionises Your Business.

The main objectives of the research report elaborate the overall market overview on Animal Stem Cell Therapy market dynamics, historic volume and value, robust market methodology, current and future trends, Porters Five Forces Analysis, upstream and downstream industry chain, new technological development, cost structure, government policies and regulations, etc. Major companies, company overview, financial data, products and services, strategy analysis, key developments market competition, industry competition structure analysis, SWOT Analysis, etc.

Further Animal Stem Cell Therapy market research report provides regional marketanalysis with production, sales, trade and regional forecast. it also provides market investment plan like product features, price trend analysis, channel features, purchasing features, regional and industry investment opportunity, cost and revenue calculation, economic performance evaluation etc.

The Animal Stem Cell Therapy industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions offered.

Report Scope

The tunnel ventilation market has been segmented based on different types and application. In order to provide a holistic view on the market current and future market demand has been included in the report.

Major players covered in this report are MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics, etc.

The Report is segmented by types Dogs, Horses, Others, and by the applications Veterinary Hospitals, Research Organizations, etc.

Our research and insights help our clients in identifying compatible business partners.

Buy this report online athttps://www.insidemarketreports.com/buy-now/4/459572/Animal-Stem-Cell-Therapy/single

Purchase this Report now by availing up to 40% Discount and free consultation. Limited offer only.

Major Points from the Table of Contents

1 Animal Stem Cell Therapy Market Overview

2 Global Animal Stem Cell Therapy Market Competition by Manufacturers

3 Global Animal Stem Cell Therapy Capacity, Production, Revenue (Value) by Region)

4 Global Animal Stem Cell Therapy Supply (Production), Consumption, Export, Import by Region

5 Global Animal Stem Cell Therapy Production, Revenue (Value), Price Trend by Type

6 Global Animal Stem Cell Therapy Market Analysis by Application

7 Global Animal Stem Cell Therapy Manufacturers Profiles/Analysis

8 Animal Stem Cell Therapy Manufacturing Cost Analysis

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

11 Market Effect Factors Analysis

12 Global Animal Stem Cell Therapy Market Forecast

13 Research Findings and Conclusion

14 Appendix

Why Inside Market Reports:

For all your Research needs, reach out to us at:

Email: [emailprotected]

Phone: +1-617-230-0741

Read the original:
How Will the Virus Epidemic Cause Animal Stem Cell Therapy Market 2020 - Owned

Global Animal Stem Cell Therapy Market Set to Touch Double Digit CAGR With Industry Insights, Trends, Outlook, and Opportunity Analysis during…

The Global Animal Stem Cell Therapy Market report focuses on market size, status, and forecast 2020-2024, along with this, the report also focuses on market opportunities and threats, tactical decision-making, and evaluating the market. The Animal Stem Cell Therapy market report delivers data and information on changing investment structure, technological advancements, market tendencies and developments, capacities, and detailed information about the key players of the global market. In addition to this, the report also involves the development of the Animal Stem Cell Therapy market in the major regions across the world.

Cutting-edge released the research study on Global Animal Stem Cell Therapy Market, which deals a exhaustive overview of the factors influencing the global business scope. Animal Stem Cell Therapy Market research report shows the latest market insights, current situation analysis with upcoming trends, and breakdown of the products and services. The Animal Stem Cell Therapy Industry Report delivers key statistics on the market status, size, share growth factors of the Animal Stem Cell Therapy .

Get a PDF Sample Copy of this Animal Stem Cell Therapy Market Report:

https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268#request_sample

Top Leading players of Animal Stem Cell Therapy Market Covered in the Report:

Medivet Biologics LLC VETSTEM BIOPHARMA J-ARM U.S. Stem Cell, Inc VetCell Therapeutics Celavet Inc. Magellan Stem Cells Kintaro Cells Power Animal Stem Care Animal Cell Therapies Cell Therapy Sciences Animacel

The report has enclosed key geographic regions such as Europe, Japan, United States, India, Southeast Asia and Europe. As far as the sub-regions, North America, Canada, Medico, Australia, Asia-Pacific, India, South Korea, China, Singapore, Indonesia, Japan, Rest of Asia-Pacific, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, Russia, Central & South America, Middle East & Africa are included.

Key Market Segmentation of Animal Stem Cell Therapy :

On the basis of types, the Animal Stem Cell Therapy Market from 2020 to 2024 is primarily split into:

Dogs Horses Others

On the basis of applications, the Animal Stem Cell Therapy Market from 2020 to 2024 covers:

Veterinary Hospitals Research Organizations

Ask For Discount:

https://www.globalmarketers.biz/discount_inquiry/discount/130268

The Animal Stem Cell Therapy Market Research Report furthermore delivers a local examination of the market with a high focus on showcase development, development rate, and development potential. The research report calculates marketplace length estimate to analyze investment potentials and growth.

In this study, the years considered to estimation the market size of the Animal Stem Cell Therapy Industry Market: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2024

The Animal Stem Cell Therapy market report provides answers to the following key questions:

Major Points Covered in Table of Contents:

For More Information and get a complete Table of content of Animal Stem Cell Therapy Market report:

https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268#table_of_contents

See original here:
Global Animal Stem Cell Therapy Market Set to Touch Double Digit CAGR With Industry Insights, Trends, Outlook, and Opportunity Analysis during...

Stem Cell Therapeutics Market Trend 2020 Covid-19 Impact Industry Insights by Share, Emerging Trends, Regional Analysis, Segments, Prime Players,…

Global Stem Cell Therapeutics Market Report 2020trend offers Complete examination of industry status and standpoint of significant areas dependent on of central participants, nations, item types, and end enterprises. This report focuses on the Stem Cell Therapeutics in Global market, especially inUnited States, Europe, China, Japan, South Korea, North America, India.Stem Cell Therapeutics Market report categorizes the market based on manufacturers, regions, type and application. Stem Cell Therapeutics Report 2020 (value and volume) by company, regions, product types, end industries, history data and estimate data.

Also, Report contains a comprehensive analysis of the important segments like market opportunities, import/export details, market dynamics, key manufacturers, growth rate, and key regions. Stem Cell Therapeutics Market report categorizes the market based on manufacturers, regions, type, and application. Stem Cell Therapeutics Market reports offer a detailed assessment of the Stem Cell Therapeutics including enabling technologies, current market situation, market assumptions, restraining factors.

Get a Sample PDF of Stem Cell Therapeutics Market 2020

List of Top Key-players in 2020 of Stem Cell Therapeutics Market:-

The Global Stem Cell Therapeutics market swot is provided for the international markets including progress trends, competitive landscape breakdown, and key in regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT REQUEST SAMPLE

The Behavioral Rehabilitation Market is expected to witness a CAGR of 13.7% during the forecast period. North America dominates the global market due to the high incidence diseases such as cancer and diabetes which can now be cured by stem cell therapies.

Increased Awareness about Umbilical Stem Cells

Currently, there is an increase in the number of clinical trials for testing future treatment possibilities of cord blood. Over 200 National Institutes of Health (NIH) funded clinical trials with cord blood are currently being conducted in the United States alone. The potential implications of the results are a cause of hope among scientists and healthcare providers. In the United Kingdom, a petition has been submitted to increase the awareness of umbilical cord cells. In United States, CordBloodAwareness.org was created out of a need to increase awareness about the life-saving power of umbilical cord blood stem cells. Thus increasing awareness about umbilical stem cells. Additionally, increase in the patient population, increase in the approval for clinical trials in stem cell research, growing demand as regenerative treatment option and rising R&D initiatives to develop therapeutic options for chronic disease are also fuelling Stem Cell Therapeutics Market globally.

Ethical and Moral Framework

Stem cells are often viewed as a hope as an alternative form of therapies. However, there has been a strong debate over the use of stem cells in the development of novel therapies. It is a matter of high priority on the political and ethical agenda of many countries. As much as there is a great scope on the therapeutic front, there is an equally strong opposing force on the ethical front. For example, embryonic stem cell research is a morally complex scenario. There are different viewpoints on this issue. Embryos are considered as a Person or as a potential Person. This is one side of the moral issue which is being catered to which is restraining the growth of stem cell therapeutics market. Additionally, expensive procedures and regulatory complications are also hindering the growth of Stem Cell Therapeutics Market.

North America is dominating the market

One of the largest driving factors for the stem cell market in the US is the high purchasing power of the citizens in the country. There is an increasing incidence diseases such as cancer and diabetes which can now be cures by stem cell therapies. There is also increased awareness about the available stem cell procedures and therapies among people which in turn increases the demand for this market. Thus North America dominates Stem Cell therapeutics Market.

Get a Sample PDF of Report @https://www.360marketupdates.com/enquiry/request-sample/12885506

The global Stem Cell Therapeutics market covers the vision of participant analysis by product types, market share, applications, sales, and revenue.

Highlighted points of Stem Cell Therapeutics Market Size:

Key Developments in the Stem Cell Therapeutics Market:

Inquire more and share questions if any before the purchase on this report@https://www.360marketupdates.com/enquiry/pre-order-enquiry/12885506

This Stem Cell Therapeutics Market Research/analysis Report Contains Answers to your following Questions

Reasons to Purchase this Report

Purchase this report (Price 4250 USD for a single-user license)@https://www.360marketupdates.com/purchase/12885506

Finally, the report Global Stem Cell Therapeutics Market 2020 describes the Stem Cell Therapeutics industry expansion game plan, the Stem Cell Therapeutics industry knowledge supply, appendix, analysis findings, and the conclusion.

About 360 Market Updates:

360 Market Updates is a credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Market Updates, our objective is to provide a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision-makers in finding the most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Info:

360 Market Updates

Mr. Ajay More

USA: +1 424 253 0807

UK: +44 203 239 8187

[emailprotected]

Floor POP Display Market Size 2020 Boosting the Growth Worldwide:Market Key Dynamics, Recent and Future Demand, Trends, Share Valuation Industry Size and Foreseen Research Report

Floor POP Display Market Size 2020 Boosting the Growth Worldwide:Market Key Dynamics, Recent and Future Demand, Trends, Share Valuation Industry Size and Foreseen Research Report

Floor POP Display Market Size 2020 Boosting the Growth Worldwide:Market Key Dynamics, Recent and Future Demand, Trends, Share Valuation Industry Size and Foreseen Research Report

Group 2 Powered Mobility Devices Market Size 2020 Analysis by Industry Trends, Size, Share, Company Overview, Growth, Development and Forecast by 2025

Potassium Carbonate Market Size 2020: Industry Trends, Growth, Size, Segmentation, Future Demands, Latest Innovation, Sales Revenue by Regional Forecast to 2025

Originally posted here:
Stem Cell Therapeutics Market Trend 2020 Covid-19 Impact Industry Insights by Share, Emerging Trends, Regional Analysis, Segments, Prime Players,...

Live-cell imaging and analysis reveal cell phenotypic transition dynamics inherently missing in snapshot data – Science Advances

INTRODUCTION

Cells of a multicellular organism can assume different phenotypes that can have markedly different morphological and gene expression patterns. A fundamental question in developmental biology is how a single fertilized egg develops into different cell types in a spatialtemporally controlled manner. Cell phenotypic transition (CPT) also takes place for differentiated cells under physiological and pathological conditions. A well-studied example is the epithelial-to-mesenchymal transition (EMT), central to many fundamental biological processes, including embryonic development and tissue regeneration, wound healing, and disease-like states such as fibrosis and tumor invasiveness (1). One additional example is artificially reprogramming differentiated cells, such as fibroblasts, into induced pluripotent stem cells and other differentiated cell types such as neurons and cardiomyocytes (2). CPT is ubiquitous in biology, and a mechanistic understanding of how a CPT proceeds emerges as a focused research area with an ultimate goal of achieving effective control of the phenotype of a cell.

Recent advances in snapshot single-cell techniques, including single-cell RNA sequencing (scRNA-seq) and imaging-based techniques, pose new questions. One such question is, how does a CPT process proceed, step by step, in the continuously changed high-dimensional gene expression (e.g., transcriptome and proteome) space? These destructive methods, however, are inherently unable to reveal the temporal dynamics of how an individual cell evolves over time during a CPT.Approaches such as pseudo-time trajectory analysis (3), ergodic rate analysis (4), and RNA velocities (5) have been developed to retrieve partial dynamical information from snapshot data.

However, some fundamental limits exist in inferring dynamical information from snapshot data (6). Figure 1 illustrates that inference from snapshot data unavoidably misses key dynamical features. A bistable system is coupled to a hidden process, e.g., epigenetic modification for a cellular system, which is slow compared to the transition process being studied (Fig. 1A). Presence of the slow variable leads to observed heterogeneous dynamics (Fig. 1B, more details of the simulation are in fig. S1). Individual trajectories show characteristic stepping dynamics, but the transition positions vary among different trajectories due to the system assuming different values for the hidden variable. Consequently, when only snapshot data are available, information about the temporal correlation of individual cell trajectories is missing, and one cannot deduce the underlying two-state dynamics (Fig. 1C).

(A) A double well potential with one observable coupled to a hidden variable with dynamics much slower than that of the process under study. Arrows represent simulations of two trajectories that start from well A and jump to B. The black line represents the boundary of the two wells. (B) One-dimensional (1D) potential slices along the observable coordinate corresponding to the transitions indicated in (A). (C) Superimposed trajectories from stochastic simulation (shown as background), with two typical trajectories highlighted corresponding to the transitions in (A). The hidden variables for the green trajectory and the magenta trajectory take the values 0.47 and 0.45, respectively. a.u., arbitrary units. (D) Stacked histograms of the observable at various time points [t0, t1, t2, t3, and t4 in (C)], reflecting the snapshot data. Blue bars were sampled from points that reside in well A. Red bars were sampled from points that reside in well B. Notice that the information as to which well a sampling point resides is obtained from the full 2D potential and cannot be accurately derived from the snapshot data.

The necessity of live-cell trajectories has been illustrated in a number of studies, such as the information capacity of a signal transduction network (7), incoherent feed-forward loops to detect only fold change but not the absolute change of an input signal (8), and stepwise cellular responses to drugs (9). Two recent studies conclude a linear path for EMT from analyzing single-cell RNA-seq and proteomic data (10, 11). Discrepancy, however, exists between this conclusion and theoretical predictions of parallel paths for a multistable system like EMT (12, 13), raising a question whether the theoretical models need to be modified or the inferred linear path is an artifact from snapshot data. Live-cell imaging is needed to address such a question.

Therefore, acquiring information from long-term CPT dynamics requires tracking individual cells through live-cell imaging, typically with time-lapse fluorescent imaging. However, identifying appropriate molecular species that faithfully reflect the process for labeling and generating such labeling can be tedious and time-consuming. In addition, multiplex and frequent fluorescent image acquisition over a long period of time, e.g., days, is necessary for characterizing a CPT process but is severely limited by the number of available fluorescence channels and cytotoxicity concerns.

In short, a technical dilemma exists: Fixed cellbased techniques provide high-dimensional expression profiles of individual cells but lack true dynamical information, while fluorescent labelingbased live-cell imaging techniques typically provide dynamical information for only a small number of dynamical variables. To tackle the substantial challenges in CPT studies, here, we develop a framework for extracting cell dynamical information through quantitative analysis of live-cell trajectories in a high-dimensional cell feature space. Our method resides on the observation that a cell state can be defined by either the expression pattern or cell morphological features. The latter broadly refers to collective cellular properties such as cell body shape, organelle distribution, etc., which are convenient for live-cell imaging, with and without labeling. Hundreds of these morphological features have been routinely used in pathology and in a number of fixed- and live-cell studies for defining and studying cell phenotypes and drug responses (9). Introduction of this framework allows one to study CPTs in the context of well-established rate theories (14). Rate theories study dynamical processes of escaping from a metastable attractor or relaxing to a newly established attractor.

We applied this framework to study transforming growth factor (TGF-)induced EMT in a human A549 derivative cell line with endogenous vimentinred fluorescent protein (VIM-RFP) labeling [American Type Culture Collection (ATCC) CCL-185EMT]. We represented the state of a cell at a given time as a point (or equivalently a vector) in a 309-dimensional composite feature space of the cell body contour shape and texture features of vimentin, an intermediate filament, and a key mesenchymal marker. While the framework is for morphological features in general, in this study, we focus on the cell body shape and use cell shape and morphology indistinctively. Through quantifying time-lapse images, aided by a deep learningbased image analysis algorithm, we were able to define the epithelial and mesenchymal regions in the state space and unravel two parallel pathways that EMT proceeds through. We provide a Python package, multiplex trajectory recording and analysis of cellular kinetics (M-TRACK), for studying CPT in the composite feature space. The framework will provide a foundation for quantitative experimental and theoretical studies of CPT dynamics.

The A549 VIM-RFP cell line (ATCC CCL-185EMT) was generated as a model system for studying EMT. It was created using CRISPR-Cas9 technology, in which the RFP sequence was inserted just before the stop codon of one allele of the endogenous vimentin gene (Fig. 2A and fig. S2A). The VIM-RFP knock-in allele was confirmed by sequencing (fig. S2B) and colocalization immunostaining of vimentin and VIM-RFP (Fig. 2B) with a Pearson correlation coefficient 0.9 and a Manders overlap coefficient 0.93.

(A) Schema of CRISPR-Cas9mediated generation of VIM-RFP knock-in allele. LHA, left homology arm; RHA, right homology arm; pA, polyadenylation signal; BSR, blasticidin resistance; exon9, exon #9 of vimentin gene. (B) Colocalization immunostaining of vimentin and endogenous VIM-RFP. Scale bar, 20 m. (C) Matrigel invasion assay of A549 VIM-RFP cells. After TGF- induction, cells show increased invasive capacity. Scale bar, 100 m. Data represent mean SD from three repeated experiments. Students t test; asterisk denotes P < 0.01.

EMT studies reach a consensus that there is a continuous spectrum of EMT phenotypes (1). Previous studies report that the parental A549 cells have already undergone partial EMT with detectable basal vimentin expression and can complete a full EMT upon TGF- treatment (11). Consistently, with recombinant human TGF-1 treatment, the A549 VIM-RFP cells showed an increased invasive capacity reflecting the functionality of mesenchymal cells (Fig. 2C) and increased Snail1 and N-cadherin expressions (fig. S2C). After 2 days of continuous treatment, most cells underwent apparent cell shape changes from round polygon shapes to elongated spear shapes, characteristic changes of EMT. These results confirmed that under TGF-1 treatment, the A549 VIM-RFP cells completed a full EMT to convert from a partial EMT to a complete mesenchymal phenotype, and this is the process that we focused on in this study.

We performed time-lapse imaging on the A549 VIM-RFP cells continuously treated with TGF-1 for 2 days, with an imaging frequency of one frame per 5 min for morphology and one frame per 10 min for vimentin (more details in Materials and Methods). To mathematically describe how a CPT (EMT here) proceeds, one needs to choose a mathematical representation of cell status at a given time. For representing the cell shape, we adopted the active shape model that has been widely used in computer-based image analyses (15) and particularly, in cell biology studies (16, 17), but here, we use it for the purpose of forming a complete orthonormal basis set (Fig. 3). That is, we first segmented the images using our modified deep convolutional neural network procedure (Fig. 3A, see Supplemental Text for details) and tracked individual cell trajectories. Each cell shape was aligned to a reference shape and was approximated by N (=150) landmark points equally spaced along the cell contour (Fig. 3B) (18). For two-dimensional (2D) images, a cell was specified by a point z = (x1, x2, , xN; y1, y2, , yN) in the 2N-dimensional morphology space (Fig. 3C). By performing principal components analysis (PCA) on the dataset of a collection of single-cell trajectories, one constructs a complete orthonormal basis set with the 2N 4 eigenvectors {a}, or the principal modes, for the morphology space. Notice that alignment fixes four degrees of freedom (center and orientation). An attractive feature of the principal modes is that they have clear physical meanings. For example, the two leading principal modes of A549 VIM-RFP cells undergoing EMT reflect cell growth along the long and short axes, respectively (Fig. 3D). Then, any cell shape that is approximated by the landmark point z(t), which is generally time dependent in live-cell imaging, can be expressed as a linear combination of these principal modes z(t)=i=12N4ci(t)ai(Fig. 3E). Therefore, c(t) = (c1(t),, c2N4(t)) forms a trajectory in the shape space expanded by the basis set {a}.

(A) Segmentation of single cells with the deep convolution neural networks (DCNN)/watershed method. (B) Extraction of cell outline from segmented mask of individual cells, followed by resampling using the active shape model and aligning all cell outlines to a mean cell shape for consistent digitization of cell morphology features. (C) Representation of single-cell shapes as points in the 2N 4dimensional morphology space. Each dot represents one cell. (D) Principal modes of morphology variation. Left: first principal mode (PC1). Right: second principal mode (PC2). The 1 represents the corresponding coordinate value on the axis of morphology PC1 or PC2. The principal modes reflect the characteristics of cell morphology variation along the PC axes. (E) A representative cell shape (left) and its reconstruction with the first seven leading principal modes. (F) A typical single-cell trajectory in the two leading morphology PC domains (left) and its corresponding contours (triangle dots marked by arrows in the left that have the same color as the contours) at various time points (right). Each dot represents an instantaneous state of the cell in the morphology space. Color bar represents time (unit in hour).

Figure 3F shows a typical trajectory projected to the first two leading principal component (PC) modes in the morphology space and their corresponding time courses of cell contour shape changes. Over time, this cell elongated along the major axis (PC1), while shortened slightly along the minor axis (PC2), resulting in a long rod shape with an enlarged cell size. Two additional trajectories in fig. S3 further reveal that single-cell trajectories are heterogeneous with switch-like or continuous transitions while sharing similar elongation of PC1 over time.

During a CPT, cell morphology changes are accompanied by global changes in gene expression profiles (19). Specifically, in A549 VIM-RFP cells that have been treated with TGF- for 2 days, vimentin was up-regulated with texture change from being condensed in certain regions of the cell to be dispersed throughout the cytosol (Fig. 4A), consistent with previous reports (2022). These previous studies used fixed cells and lack temporal information about the vimentin dynamics. Therefore, we recorded the change in vimentin within individual cells with time-lapse imaging.

(A) Flowchart of quantification. Left: typical vimentin fluorescence images of single cell before (top) and after treatment of TGF- (4 ng/ml) for 2 days (bottom; scale bar, 50 m). Middle: segmented single-cell image with only pixels inside the cell mask kept for Haralick feature calculations. Right: framework of calculating the single-cell Haralick features. All pixel values inside an individual segmented cell were used to calculate GLCM and Haralick features. (B) A typical single-cell trajectory on the plane of vimentin Haralick features PC1 and PC2 (left) and on the plane of PC3 and PC4 (right). Color bar represents time (units in hours). Large triangular dots labeled with numbers correspond to 0, 12, 24, 36, and 48 hours, respectively. Each dot represents an instantaneous state of the cell in the Haralick feature space. (C) Segmented single-cell images of vimentin at various time points corresponding to the trajectory in (B) (labeled with large, triangular dots).

Texture features are widely used for image profiling in drug screening, phenotype discovery, and classification (2325). We hypothesized that the texture features of vimentin can be quantified as an indicator of EMT progression. For quantification, we used Haralick features on the basis of the co-occurrence distribution of gray levels (see Materials and Methods for detailed information of Haralick features used). After segmentation, we calculated the gray-level co-occurrence matrix (GLCM) in the mask of each cell and 13 Haralick features based on the single-cell GLCM and averaged all four directions (Fig. 4A, see Materials and Method for details). Nearly every Haralick feature shows a shift in distribution after TGF- treatment (fig. S4).

To capture the major variation in vimentin Haralick features during EMT, we performed linear dimension reduction with PCA (more details are in Materials and Methods). Figure 4 (B and C) shows a typical single-cell trajectory in the vimentin Haralick feature space and corresponding segmented single-cell images at various time points along this trajectory, respectively. The dynamics in the vimentin feature space are again heterogeneous, as indicated here, and from two additional trajectories in fig. S5.

Overall, we described a cell state in a 309-dimensional composite feature space of cell morphology and vimentin texture features. The cells occupy distinct regions in the composite feature space at the initial (0 to 2 hours) and final stages (46 to 48 hours) of TGF- treatment (4 ng/ml) (Fig. 5A). Physically, upon TGF- treatment, the cell population relaxes from an initial stationary distribution in the composite feature space into a new one, and this study focuses on the dynamics of this relaxation process.

(A) Kernel density plots in the plane of morphology PC1 and vimentin Haralick feature PC1 estimated from 3567 single-cell states from 196 trajectories (represented by dots), at 0 to 2 hours (top, 1920 single-cell states) and 46 to 48 hours after addition of TGF- (bottom, 1647 single-cell states). (B) Distributions of cells at 0 to 2 hours and 46 to 48 hours cells after adding TGF- in various features (morphology PC1, vimentin Haralick PC1, PC3, and PC4). The diagonal axes are plots of kernel density estimation of the 1D distribution of the corresponding features. The four PC modes capture 82.7% of morphology variance, 57.0, 8.8, and 5.2% of total vimentin feature variance, respectively. The distributions along vimentin PC2 for cells before and after treatment largely overlap with each other and were not included here. A complete combination of distributions is shown in fig. S6. (C) Scatter plot of 0- to 2-hour data (left) and 46- to 48-hour data (right) on the plane of morphology PC1 and vimentin Haralick features PC1. Color represents the region a cell resides at a given time point, as predicted by the fitted label-spreading function. E, epithelial region; I, intermediate region; M, mesenchymal region. (D) A single-cell trajectory with its residing regions predicted by the label-spreading function on the domain of morphology PC1 and vimentin Haralick features PC1 and PC3 (with regions represented by different colors).

Close examination reveals major distribution shifts along four coordinates: morphology PC1 (82.7% variance of morphology), vimentin Haralick PC1 (57.0% variance), PC3 (8.8% variance), and PC4 (5.2% variance) (Fig. 5B and fig. S6). This observation permits subsequent analyses that are restricted to these collective coordinates.

In rate theories, to define a reactive event, one typically divides the configuration space describing a reaction system into reactant, intermediate, and product regions (26, 27). Specifically, for the present system, we developed a computational procedure that combines the Gaussian mixture model (GMM) analysis of the cell distributions (fig. S7, A and B) followed by fitting a label-spreading function (28) using the k-nearest neighbor (KNN) method (Material and Methods). This label-spreading function takes coordinates (a multidimensional vector) of individual cells in the composite feature space as input and predicts the label of a cell, i.e., the region identity (E, I, or M discussed below) in which it resides (see Material and Methods for details). Combining the biology characteristics of EMT, this procedure divides the four-dimensional space into epithelial (E; or more precisely partial E for A549 VIM-RFP), intermediate (I), and mesenchymal (M) regions (Fig. 5C). Figure 5D shows a trajectory that starts within the E region and then progresses to the I and then to the M regions.

Consistent with a standard definition of reactive events in rate theories, we defined an ensemble of reactive trajectories as all the single-cell trajectories similar to the one in Fig. 5D (and fig. S7C) that leave the E region and end in the M region before returning to E. Overall, we recorded NT (=196) acceptable continuous trajectories (see Materials and Methods); among them, NR (=139) are reactive trajectories (movies S1 and S2).

Single-cell trajectories in the composite feature space show clear heterogeneous transition dynamics. In one representative trajectory (Fig. 6A and fig. S8A, left), the cell transits from the E to the M region following a series of transitions first along the vimentin Haralick PC1 and then the morphology PC1. In contrast, in another trajectory (Fig. 6B and fig. S8A, right), the cell proceeds with concerted morphological and vimentin Haralick feature changes.

(A) A typical single-cell trajectory in which the major change along the vimentin Haralick PC1 precedes the major change along the morphology PC1 (class I). (B) A typical single-cell trajectory in which the morphology PC1 and vimentin Haralick PC1 show concerted variation (class II). (C) Projection of recorded 139 reactive trajectories on 2D t-SNE space using the DTW distances. Each dot is a single-cell trajectory that undergoes EMT. Color represents labels of k-means clustering on the DTW distances. (D) Mean trajectories of class I and II trajectories, respectively. They were calculated using the soft-DTW barycenter method. (E) Plausible mechanistic model. In this network, both morphology and vimentin changes are induced by TGF-, and they both activate each other and themselves. (F) Transition paths simulated with the model in (E). The transition paths show dynamical characteristics similar to those observed experimentally.

To systematically study the two types of distinct behaviors, we used soft-dynamic time warping (DTW) (29) to calculate the distance between different trajectories, and t-distributed stochastic neighbor embedding (t-SNE) to project the trajectory distance matrix to 2D space (30). We found that these trajectories form two communities (Fig. 6C). A k-means clustering on these trajectories separated them into two groups, consistent with the two communities in the t-SNE space. The two groups of trajectories reveal different dynamical characteristics. In one group (class I), vimentin Haralick PC1 varies first, followed by marked change of morphology PC1. In the other group (class II), for most trajectories, the morphology PC1 and vimentin Haralick PC1 change concertedly, while for only a small percentage, the morphology PC1 changes earlier than vimentin Haralick PC1 (fig. S8B). Distinction between the two groups of trajectories is apparent from the scattered plot in the morphology PC1/vimentin Haralick PC1 plane (fig. S8C) and the nonoverlapping mean trajectories obtained using the soft-DTW barycenter (Fig. 6D and fig. S8D) (29, 31).

To rule out the possibility that the existence of two classes of trajectories is an artifact of DTW, we analyzed cross-correlation between morphology PC1 and vimentin Haralick PC1 of individual reactive trajectories. Cross-correlation analysis calculates the time delay at which the correlation between morphology PC1 and vimentin PC1 reaches a maximum value (32). The time delay shows a stretched distribution (fig. S8E). A large portion of trajectories have vimentin Haralick PC1 change before morphology PC1 change, while another main group of trajectories has the time delay between morphology PC1 and vimentin Haralick PC1 close to zero. After separating the trajectories into two groups based on the sign of time delay, the mean trajectories of the two groups (fig. S8E), referred to as transition paths that connect the initial and final cell states, are similar to what was obtained with k-means clustering on the DTW distance.

Therefore, a main conclusion of this study is that the live-cell platform revealed two types of paths for the TGF-induced EMT in A549 VIM-RFP cells. Figure 6E shows a plausible mechanistic model summarizing the existing literature (see Materials and Methods for details and references therein). TGF- activates morphological change and vimentin to induce EMT, while morphological change and vimentin expression can induce each other and themselves. Computer simulations with the model followed by k-means clustering on DTW distance reproduce the two parallel EMT paths (Fig. 6F and fig. S9, C and D). The cross-correlation analysis also showed results similar to what was observed experimentally (fig. S9E). That is, the live-cell imaging platform presented here can provide mechanistic insight for further analyses.

We also compared our analysis on trajectories with snapshot data analysis. Similar to Fig. 1, we extracted single-cell data from the live-cell trajectories every 6 hours, treated them as snapshot data with no information of temporal correlation, and performed pseudo-time analysis with Scanpy and Wishbone (33, 34). The pseudo-time results (fig. S10, A and B) show only gradual change from epithelial to mesenchymal regions. We then enforced a two-branch analysis with Wishbone (fig. S10C), but the results are difficult for biologically meaningful interpretation. These results corroborate with Fig. 1 and demonstrate that some dynamical features revealed from live-cell imaging can be missing from snapshot data due to lack of temporal correlation information in the latter.

Compared to the recent advances of fixed cellbased single-cell techniques, live-cell imaging remains underdeveloped especially in studying CPTs, due to technical challenges. Specifically, the degrees of freedom specifying cell coordinates should be experimentally feasible for live-cell measurement and faithfully represent cell states. However, individual gene products typically only reflect partial dynamical information of a CPT process, and simultaneous fluorescence labeling of multiple genes is challenging. Recently, tracking cell morphological features through live-cell imaging emerges as a means of extracting temporal information about cellular processes in conjunction with expression-based cell state characterization (9, 3538). Cellular and subcellular morphologies reflect collective gene expression pattern and cell phenotype (3941). Furthermore, hundreds or more of morphology features such as cell size and shape can be conveniently extracted from bright-field images without necessity of additional fluorescence labeling. Here, we further developed a quantitative framework for recording and analyzing single-cell trajectories in a composite feature space, including cell shape and texture features and a computational package for related image analyses.

Our application to the TGF-induced A549 VIM-RFP EMT process demonstrates the importance of extracting dynamical information from live-cell data. A cell has a large number of molecular species that form an intricately connected network, and it interacts with a fluctuating extracellular environment, including cell-cell interactions. Consequently, even isogenetic cells show cell-cell heterogeneity, which further manifest as large trajectory-to-trajectory heterogeneity in single-cell CPT dynamics, and some dynamical features characteristic to a particular process might be unavoidably concealed from snapshot data. Our live-cell data reveals information on the two distinct types of paths of EMT with distinct vimentin dynamics. We then constructed and analyzed a mechanistic model on the basis of the previous reports that vimentin is a regulator and marker of EMT, and the model predicts these parallel paths. Further studies, however, are needed to investigate whether alternative mechanistic models can also explain the observations and examine whether these parallel paths exist in other EMT processes, in addition to TGF-induced EMT with the A549 VIM-RFP cells. One can also apply the framework to investigate the reverse process, mesenchymal-to-epithelial transition (MET), and examine whether MET follows different paths, as predicted from analyzing snapshot data (11).

While we present a general framework here, it has some limitations and needs further development. In this study, we restricted specification of the state of a cell by its cell shape and vimentin texture features. Application with recently developed imaging techniques, aided by machine learningbased computational algorithms, may provide additional features such as organelle texture and distributions in three dimensions from long-term label-free imaging, as demonstrated by a recent work of Sandoz et al. (42) using holotomographic microscopy to study multiorganelle dynamics. Cell cycle is a possible hidden variable contributing to the observed cell-cell heterogeneity in this study and can be tracked with proper reporters. Adding these new dimensions of information can provide finer resolution of cell state in an expanded cell state space.

Another limitation of the morphology/texture-based live-cell imaging framework is that it provides mostly indirect information on the dynamics of involved molecular species. For example, further mechanistic understanding of the observed parallel paths requires information on how the cell expression pattern changes along the paths. One can use the paths identified from live-cell imaging data, rather than currently used pseudo-trajectory approaches based on a perceived expression-similarity criterion, to time-order snapshot single-cell data, thus resolving the dilemma experienced in single-cell studies. For this purpose, one needs to establish a mapping system between the composite feature space and the expression space.

In summary, in this study, we demonstrate that live-cell imaging is necessary to reveal certain dynamical features of a CPT process concealed in snapshot data due to cell-cell heterogeneity. Meanwhile, we present a framework that facilitates recent emerging efforts of using live-cell imaging to investigate how a CPT process proceeds along continuous paths at multiplex, albeit lower-dimensional feature space, complementing fixed cellbased approaches that can provide snapshots of genome-wide expression profiles of individual cells. We expect that the framework can be generally applied since marked morphological changes typically accompany a CPT process.

The human nonsmall cell lung carcinoma lines, A549 (ATCC CCL-185) and A549 VIM-RFP (ATCC CCL-185EMT), were from ATCC. Cells were cultured in F-12K medium (Corning) with 10% fetal bovine serum (FBS) in MatTek glass bottom culture dishes (P35G-0-10-C) in a humidified atmosphere at 37C and 5% CO2. Culture medium was changed every 3 to 5 days. During imaging, antibiotic-antimycotic (100) (Thermo Fisher Scientific, 15240062) and 10 mM Hepes (Thermo Fisher Scientific, 15630080) were added to the culture medium.

The CHOPCHOP website (https://chopchop.cbu.uib.no/) was used to design high-performance single guide RNAs (sgRNAs) to target the sequence near the stop codon of the human vimentin gene. The cleavage activities of the gRNAs were validated using the T7 endonuclease 1 (T7E1) assay according to the manufacturers instructions (New England Biolabs, no. E3321). The sgRNA VIM-AS3 (5-CTAAATTATCCTATATATCA-3) was chosen in this study. To generate the sgRNA-expressing vector, VIM-AS-3 gRNA oligos were designed, phosphorylated, annealed, and cloned into the PX458 (Addgene, catalog no. 48138) vector, using Bbs I ligation. Multiple colonies were chosen for Sanger sequencing to identify the correct clones, using the primer U6 (forward): 5-AAGTAATAATTTCTTGGGTAGTTTGCAG-3.

The VIM-RFP knock-in donor was designed and constructed to contain approximately 800base pair left and right homology arms, a Cayenne RFP gene (ATUM, no. FPB-55-609), preceded by a 22amino acid linker, and followed by a bovine growth hormone polyadenylation signal sequence. To assist in drug-based selection of gene-edited cell clones, human elongation 1-alpha (EF1)blasticidin selection cassette, flanked by Loxp sites, was also cloned into the vector and positioned upstream of the right homology arm.

CRISPR-Cas9 technology was used to incorporate the RFP reporter into the 3 terminal end of the vimentin gene. Briefly, A549 cells were plated at a density of 2 105 cells per well in a six-well plate. After 24 hours, cells were transfected with 4.0 g of PX458_VIM-AS3 plasmid, 4.0 g VIM-RFP knock-in donor plasmid, and 24 l of transfeX (ATCC ACS-4005). Blasticidin selection (10 g/ml) was applied 24 hours after transfection. RFP-positive cells were single-cell sorted and expanded for molecular characterization.

RFP positive A549 VIM-RFP cells were harvested, and DNA was extracted using QuickExtract (Epicentre, QE09050). Primers were designed for left homology arm and right homology arm junction polymerase chain reaction (PCR): left junction: 5-TAGAAACTAATCTGGATTCACTCCCTCTG-3 (forward) and 5-ATGAAGGAGGTAGCCAGGATGTCG-3 (reverse); right homology: 5-ATTGCTGCCCTCTGGTTATGTGTG-3 (forward) and 5-ATTACACCTACAGTTAGCACCATGCG-3 (reverse). Junction PCR was performed using the Phire Hot Start II DNA Polymerase (Thermo Fisher Scientific), and the PCR amplicons were subjected to Sanger sequencing for identification of clones that contained the expected junction sequences at both left and right homology junctions.

A549 VIM-RFP cells were washed with phosphate-buffered saline (PBS), fixed with 4% formaldehyde, and blocked with 5% normal goat serum/0.1% Triton X-100 in PBS for 30 mins. Afterward, the primary antibodies were added to the blocking buffer, and cells were incubated for 1 hour at room temperature. Cells were subsequently washed and incubated with the secondary antibodies for 1 hour and wrapped in aluminum foil. After washing, images were taken with a Nikon Ti-E microscope (Hamamatsu Flash 4.0V2). The primary antibodies were rabbit anti-vimentin (D21H3) (1:500 dilution; Cell Signaling Technologies, catalog no. 5741), mouse anti-N-cadherin (13A9) (1:100 dilution; Cell Signaling Technologies, catalog no. 14215), and mouse anti-Snail (L70G2) (1:300 dilution; Cell Signaling Technologies, catalog no. 3895). For secondary antibodies, goat anti-mouse or goat anti-rabbit Alexa Fluor 488 (Thermo Fisher Scientific, catalog no. A-21235) was used at a 1:1000 dilution.

A549 VIM-RFP cells were plated at a density of 1 104 cells/cm2 and maintained in F-12K medium (ATCC 30-2004) supplemented with 10% FBS (ATCC 30-2020). After 24 to 48 hours, culture medium was replaced with fresh medium supplemented with TGF- (4.0 ng/ml; R&D Systems 240-B) for 1 to 3 days to induce EMT. A549 VIM-RFP cells treated with PBS were used as a control.

Control and EMT-induced A549 VIM-RFP cells were seeded into inserts of Boyden chambers (BD Biosciences, San Jose, CA) that were precoated with Matrigel (1 mg/ml), at 5 104 cells per insert in culture medium without FBS. Inserts were then transferred to wells with culture medium containing 10% FBS as a nutritional attractor. After 24-hour incubation, invading cells on the bottom side of the insert membrane were fixed with 4% paraformaldehyde for 2 min, permeabilized with 100% methanol for 20 min, and stained with 0.05% crystal violet for 15 min at 37C. Noninvading cells on the top side of the membrane were removed by cotton swab. Photographs were taken from five random fields per insert. Cells in the five random fields were counted.

The colocalization analysis was performed with JACoP (plugin of ImageJ) (43, 44). The Pearson correlation coefficient and Manders overlap coefficient were calculated following the method described in (45).

Time-lapse images were taken with a Nikon Ti-E microscope (Hamamatsu Flash 4.0V2) with differential interference contrast (DIC) and tetramethyl rhodamine isothiocyanate (TRITC) channels (excitation wavelength is 555 nm and emission wavelength is 587) (20 objective, numerical aperture = 0.75). The cell culture condition was maintained with the Tokai Hit Microscope Stage Top Incubator. Cells were imaged every 5 min with the DIC channel and every 10 min with the TRITC channel. The exposure time for DIC was 100 ms and that for the TRITC channel was 30 ms. That is, each full (2 days long) single-cell trajectory contains 577 DIC images and 289 fluorescent images. While taking the images, all the imaging fields were chosen randomly.

We segmented single cells using a previously developed method combining deep convolution neural networks (DCNNs) and watershed (46). To quantify cell morphology, we adopted the active shape model method (15, 18). After single-cell segmentation, the cell outline was extracted and resampled into 150 points. All the single-cell outlines were aligned to a reference outline (calculated on the basis of the average of several hundred cells). The 150 points (x and y coordinates) are the 300 features of cell morphology.

For single-cell tracking, we used the TrackObjects module in CellProfiler on the segmented images using a linear assignment algorithm (47, 48). In long-term imaging, the accurate tracking of cells can be lost for several reasons, such as cells moving in or out of the field of view or inaccurate segmentation. We kept trajectories that were continuously tracked with the starting point no later than 12 hours and the end point no earlier than 30 hours after adding TGF-. These 196 trajectories were used for subsequent PCA. Among them, 139 were identified as reactive trajectories.

Haralick features have been widely used for classifying normal and tumor cells in the lungs (49) and the subcellular features or patterns such as protein subcellular locations (50, 51). After cell segmentation, each cell was extracted, and its Haralick features were calculated using mahotas (52). Haralick features describe the texture as coarse or smooth and complexity of images, and we used the following 13 features: 1, angular second moment; 2, contrast; 3, correlation; 4, sum of squares: variance; 5, inverse difference moment; 6, sum average; 7, sum variance; 8, sum entropy; 9, entropy; 10, difference variance; 11, difference entropy; 12, information measure of correlation 1; and 13, information measure of correlation 2 (50). Haralick feature calculation was based on the GLCMs (53). The GLCMs size was determined by the number of gray levels in the cell image. Because of cell heterogeneity, the numbers of gray levels varied in different cells. Because the GLCM has four directions (0, 45, 90, and 135), the Haralick features were averaged on all four directions to keep rotation invariance.

Because of cell heterogeneity, it is more informative to examine the temporal change of an individual cell relative to its initial state, such as the basal level of gene expression in signal transduction studies (8, 54, 55). For the present system, it is the initial position in the composite feature space. We used a stay pointsearching algorithm (56) to find the initial stay point of each cell in the space of cell shape and vimentin Haralick features. For each trajectory, we scaled all the landmark points by the square root of the area of the initial stay point. Physically, the latter is a characteristic length of the cell, and the scaling reflects the observation that the cell size does not affect EMT (57). All the vimentin Haralick features were reset so that the values at the initial stay point assume zero. The PCs were calculated after scaling. The scaling allows one to examine the relative temporal variation of single cells.

PCA was performed on all NT trajectories, i.e., a total of Nc (49,689 cells) with 300 morphology features (Nc 300 matrix) for linear dimensionality reduction (58). The first seven components explained more than 98% of the variance. Specifically, the first and second components explained 82.7 and 10.5% of the variance, respectively. After calculation of Haralick features for each cell, PCA was calculated on the Nc 13 matrix for linear dimension reduction.

We fitted the distribution on each of the four morphology/texture coordinates with a two-component (c0, c1) GMM separately (fig. S7A) (58) and used the four GMMs to define the E, I, and M states (fig. S7B).

For each single cell in the space of morphology PC1, vimentin Haralick PC1, PC3, and PC4 X(xii = 1,2,3,4), the label of each coordinate Li is defined using the GMM with the following equationsLi({xi{p(xi{ci,0)>0.5}{xi0.9}{x>ci,1})=2(2)where p(xici, ) is the posterior probability of certain component of xi, and ci,0 and ci,1 are the mean values of the two components of ith GMM. The label of complementary set is defined as 1.

With the labels defined on all four coordinates, we first defined the E state asS({L1=0}{L2=0}{L3=0}{L4=0})=E(3)the M state asS({L1=2}{L2=2}{L3=2}{L4=2})=M(4)and the I state otherwise. However, this definition suffers from one weakness in that it assigns the same weight to vimentin Haralick PC1, PC3, and PC4, although vimentin Haralick PC3 and PC4 count for less variance than the PC1 does. Because of this equal weight distribution, small fluctuations in vimentin Haralick PC3 and PC4 could lead to unstable assignment of cell states.

To solve this problem, we use the above definition as an initial estimate of cell state to fit to a label-spreading function (28, 58). When fitting the label-spreading function, we adopted the KNN method (50 neighbors) and used a high clamping factor (0.5) to assure the global and local consistency. The KNN algorithm in the label-spreading function allows one to take the different scales of vimentin Haralick PC1, PC3, and PC4, and community structure into consideration (Fig. 5C). Since PC1 is more important in defining the range of neighbors, the weight of PC1 in the definition was automatically increased. This change in definition avoids a situation in which cells belonging to a common community and close to each other in the composite feature space get assigned to different cell states.

The cross-correlation was used to calculate the time delay between different signals. We observed different transition time of morphology PC1 and vimentin Haralick PC1. The cross-correlation of the two time series (of morphology PC1 and vimentin Haralick PC1) was calculated (59). The time lag between the two signals was set for when the value of cross-correlation reaches the maximum (32). We separated all the trajectories by the sign of time delay between morphology PC1 and vimentin Haralick PC1.

While a cellular system is far from thermodynamic equilibrium, for simplicity, we illustrated the effect of cell-cell heterogeneity due to hidden slow variables with the following model system (https://github.com/opnumten/M-TRACK).

The potential function isU=(o2h)4(o2h)32(o2h)2+3y4(5)where o is the observable and h is the hidden slow variable (Fig. 1A).

The simulations were performed using the following procedures:

1. Generate initial condition (o0, h0) in the left well of this potential of multiple trajectories (4711) (fig. S1) with the Metropolis-Hastings algorithm (60).

2. For each initial condition, with fixed hidden slow variable h0, propagate the observable o with Langevin simulations along the 1D potential and with a Gaussian white noise ((t))o(t+dt)=o(t)+dt(4(o2h0)+3(o2h0)24(o2h0)3)+dt(t)(6)where dt is 0.01.

3. Propagate each trajectory to t = 10.

We built the network model by summarizing the existing literatures. The EMT morphology variation is mainly contributed to by generation of filament actin and E-cadherin down-regulation, which can activate the YAP/TAZ (yes-associated protein/transcriptional coactivator with PDZ-binding motif) pathway (61). The YAP/TAZ pathway can induce translocation of Smad2 (mothers against decapentaplegic homolog 2), which plays important roles in EMT (62, 63). Thus, morphology variation can activate both vimentin and itself. Vimentin can induce the EMT morphological change through regulating 1-intergrin and E-cadherin (64). Vimentin can be activated upon TGF- induction through Slug and it also activates Slug through dephosphorylation of extracellular signalregulated kinase, which forms a self-activation loop (65). Vimentin is required for the mediation of Slug and Axl (64, 6668), and it can induce variation of cell morphology, motility, and adhesion (68). Vimentin fibers regulate cytoskeleton architecture (64), and more vimentin fibers are assembled in A549 cells during EMT (20).

Next, we formulated a mathematical model corresponding to the networkdMdt=m+m+vmV2V2+Kvm2+cmM4M4+Km4mM(7)dVdt=v+v+mvM2M2+Kmv2+cvV4V4+Kv4vV(8)where m (=0.1) and v (=0.12) are the basal generate rates of morphology variable and vimentin, separately; m and v are the generate rates of morphology change and vimentin activated by TGF-, respectively; vm (=2.0) and mv (=1.0) are the activation coefficients of vimentin and morphology to each other; cm (= 3.8) and cv (= 4.0) are the self-activation coefficients of morphology and vimentin, respectively; and Kvm (=8.0), Kmv (=8.0), Kv (=2.4), and Km (=2.4) are the half-maximal effective concentrations of the Hill function. m (1.0) and v (=1.0) are degradation rates of morphology and vimentin, respectively.

The Langevin simulations were performed as follows:

1. We set m and v as 0 for simulating the control condition (i.e., without TGF- treatment). Initialize a trajectory with random point (M0 and V0) sampled from a uniform distribution within a range of [0,5). Run simulations with the following equationM(t+dt)=M(t)+dt(m+m+vmV2V2+Kvm2+cmM4M4+Km4mM)+dt(t)(9)dt(v+v+mvM2M2+Kmv2+cvV4V4+Kv4vV)+dt(t)(10)where dt was set to be 0.01, and (t) was the normal Gaussian white noise. The duration of simulation was set to 100. At the end of the simulation, the cell state relaxed to the basin of the epithelial state (fig. S9A), which was then set as the initial condition under TGF- treatment.

2. After generating multiple initial conditions from the first step, we increased the values of m(to 0.6) and v(to 1.0) to simulate the condition of TGF- treatment. If the cell gets into the range that its distance to the attractor of the mesenchymal state (Fig. 6F and fig. S9B) is less than one, then this trajectory was considered to be a trajectory of EMT.

3. After getting Nsimu (=185) reactive EMT trajectories, we performed analysis with the simulated trajectories similar to what we did with the experimental trajectories.

We obtained the steady-state probability distribution Pss by solving the diffusion equation (using Matlab 2018a PDEtool)P(M,V,t)t=(P(M,V,t)F(M,V))+D22P(M,V,t)(11)where F(M,V)=(dMdt,dVdt), and D is the diffusion coefficient. With the steady-state probability distribution, we obtained the quasi-potential of EMT defined as U ln (Pss) (69, 70). Without TGF-, there exists a deep basin as epithelial state and a shallow basin as mesenchymal state in the quasi-potential landscape (fig. S9A). After TGF- treatment, the landscape is changed, on which the mesenchymal basin becomes deep, and a valley is formed where the vimentin level is high (Fig. 6E and fig. S9B).

The snapshot data were extracted from live-cell trajectories with a time step of 6 hours. We processed the data with Scanpy and Wishbone (33, 34). The root cell in Scanpy or the start cell in Wishbone was set as the cell that is closest to the average of data at 0 hour in feature space. The number of neighbors was set to 50 in constructing a neighborhood graph in Scanpy. In addition, the number of way points in Wishbone was set to 200.

The M-TRACK program is written in Python 3 and provided with a graphical user interface. It provides tools for analyses of cell morphology with the active shape model, distribution and texture features of protein or gene florescence in single cell, and single-cell trajectories in the PC domain. The input files include the original gray-level images, segmented cell mask, and a database file of tracking results from Cellprofiler. The computer package can be downloaded from GitHub (https://github.com/opnumten/M-TRACK). Part of the source code is adapted from CellTool (18).

Statistical analyses were performed mainly with Python package, including SciPy and scikit-learn (58, 59). Students t test was used to calculate the statistical difference between different groups of samples. The samples for imaging were randomly selected to avoid bias.

More here:
Live-cell imaging and analysis reveal cell phenotypic transition dynamics inherently missing in snapshot data - Science Advances

Rising Demand for Organic and Natural Ingredients to Fuel the Growth of the Animal Stem Cell Therapy Market 2017 2025 – Scientect

The Animal Stem Cell Therapy Market globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency.

Given the debilitating impact of COVID-19 (Coronavirus) on the Animal Stem Cell Therapy market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Animal Stem Cell Therapy market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14941

The worldwide Animal Stem Cell Therapy market is an enlarging field for top market players,

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14941

This Animal Stem Cell Therapy report begins with a basic overview of the market. The analysis highlights the opportunity and Animal Stem Cell Therapy industry trends that are impacted the market that is global. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Animal Stem Cell Therapy insight regarding the things which are driving and affecting the earnings of the market. The Animal Stem Cell Therapy report comprises sections together side landscape which clarifies actions such as venture and acquisitions and mergers.

The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14941

Research objectives and Reason to procure this report:-

Finally, the global Animal Stem Cell Therapy market provides a total research decision and also sector feasibility of investment in new projects will be assessed. Animal Stem Cell Therapy industry is a source of means and guidance for organizations and individuals interested in their market earnings.

Go here to see the original:
Rising Demand for Organic and Natural Ingredients to Fuel the Growth of the Animal Stem Cell Therapy Market 2017 2025 - Scientect